As we previously identified that many of these pathways in gliomas of patients were associated with aberrant expression of TMEM230 and RNASET2, in our current study we investigated whether these pathways would also be identified in fibroblast clusters of HER2+ breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.